Gel imaging system helps detect ocular-disease causing proteins

Article

British image analysis solutions manufacturer Syngene has announced that the Dyversity 2D gel imaging system is being used in Mexico to assess the proteins linked to ocular diseases.

British image analysis solutions manufacturer Syngene has announced that the Dyversity 2D gel imaging system is being used in Mexico to assess the proteins linked to ocular diseases.

The Institute of Ophthalmology (Fundación Conde de Valenciana), Mexico, uses the imaging system to view proteins stained with silver or Coomassie blue on 2D and 1D gels. Dyversity can also analyse chemiluminescent protein arrays and Western blots. The data retrieved from the gels and blots help identify which proteins cause certain ocular diseases.

Dr Victor Bautista de Lucio, Professor Researcher at the Institute, said: “We extract tears from patients with eye diseases and study the protein profiles in their tears. This means we often need an imaging system that can detect very small amounts of proteins in our 2D gels. We had an image analyser but it was not sensitive enough and sometimes we even had to go back to using manual Polaroid plates to help us visualise the protein spots, which made image analysis very difficult.”

The system will enable the institute to create good quality proteomic profiles in a range of ocular diseases.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.